Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 9.768
- Book/Share 2.5668
- PB 15.5253
- Debt/Equity 1.9244
- CurrentRatio 1.8751
- ROIC 0.0638
- MktCap 8737945006.0
- FreeCF/Share 0.5811
- PFCF 66.4296
- PE 67.419
- Debt/Assets 0.5006
- DivYield 0
- ROE 0.2467
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | HIMS | KeyBanc Capital Markets | -- | Sector Weight | -- | -- | Oct. 21, 2025 |
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Hims & Hers: Still Growing After Breakup With Novo Nordisk
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers is positioned as a leading telehealth platform targeting millennial and Gen Z consumers with affordable, accessible healthcare solutions. The company's strong revenue growth, expanding product offerings, and direct-to-consumer model support my positive outlook on the stock. HIMS's focus on recurring subscription revenue and high customer retention rates enhances long-term financial stability and growth potential.
Read More
Hims & Hers: GLP-1 Strategy Is On Dubious Grounds
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. The results reflect GLP-1 concerns. Hims & Hers' GLP-1 strategy is now on dubious grounds after Novo Nordisk ended the companies' partnership. The overall growth story continues regardless. Hims & Hers is launching new products and markets, while U.S. momentum has remained good in most other categories.
Read More
Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: August 06, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 6, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) have opportunity to lead the securities fraud class action lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
Published: August 06, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Wait Out The GLP-1 Storm - Buy The Hims And Hers Post-Earnings Dip
Published: August 05, 2025 by: Seeking Alpha
Sentiment: Positive
Hims and Hers faced a short-term revenue dip due to regulatory changes and GLP-1 customer offboarding, but core growth remains strong. Subscriber numbers surged 31% quarter-over-quarter, and product diversification continues to drive long-term revenue expansion. Regulatory-driven shipment cadence changes should normalize by late 2025, supporting a rebound in average revenue per customer and total revenue.
Read More
HIMS Stock Plunges Following Q2 Earnings Miss, Gross Margin Down
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Hims & Hers misses second-quarter 2025 EPS and revenue estimates as gross margin narrows, despite strong online sales and subscriber growth.
Read More
Weighing HIMS GLP-1 Trends, NVO Partnership & Other Businesses
Published: August 05, 2025 by: Schwab Network
Sentiment: Neutral
Michael Cherny sees opportunity for Hims & Hers (HIMS), as long as it can overcome headwinds facing its non-weight loss businesses. He argues the stock hasn't traded on fundamentals and weighs heavily on its GLP-1 drugs sales.
Read More
Deadline Alert: Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”).
Read More
Hims & Hers drops on revenue miss
Published: August 05, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Brandon Gomez joins 'Squawk on the Street' to discuss the latest earnings from Hims & Hers.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
What's Next For HIMS Stock?
Published: August 05, 2025 by: Forbes
Sentiment: Negative
Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong growth but did not meet revenue forecasts. The company disclosed revenue of $544.8 million, which reflects a strong 73% increase compared to the previous year, although it did not reach the $552 million consensus estimate.
Read More
Hims & Hers shares fall on mixed Q2 report, light revenue forecast
Published: August 05, 2025 by: Proactive Investors
Sentiment: Negative
Hims & Hers (NYSE:HIMS) shares fell 12% before US markets opened on Tuesday as the company posted mixed results for the second quarter and issued cautious guidance. The company reported revenue of $544.8 million, up 73% year-over-year, but short of Wall Street estimates of $552 million.
Read More
Wall Street sets HIMS' stock price for the next 12 months
Published: August 05, 2025 by: Finbold
Sentiment: Negative
As telehealth company Hims & Hers Health (NYSE: HIMS) navigates a turbulent short-term period following a disappointing Q2 2025 earnings report, some on Wall Street are projecting extended losses for the stock.
Read More
Hims & Hers Health, Inc. (HIMS) - Lawmakers Urge Crackdown On Illegal Weight Loss Drugs, Novo's Termination of Collaboration With HIMS Triggers Securities Class Actions -- Hagens Berman
Published: August 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- This latest development follows an announcement by Novo Nordisk on June 23, 2025, the Danish maker of the FDA-approved weight-loss medication Wegovy® (a GLP-1 treatment for obesity), that it terminated its collaboration with Hims & Hers due to concerns about its sales and “deceptive” marketing of Wegovy®. Novo Nordisk's announcement triggered securities class action lawsuits against Hims & Hers Health, Inc. and certain of the company's executives, seeking to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025.
Read More
Hims & Hers Health, Inc. (HIMS) – Lawmakers Urge Crackdown On Illegal Weight Loss Drugs, Novo's Termination of Collaboration With HIMS Triggers Securities Class Actions – Hagens Berman
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- On July 25, 2025, investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares significantly fall during intraday trading on reports that U.S. lawmakers urged the FDA to act against copycat versions of weight loss drugs, citing safety concerns.
Read More
Lead Plaintiff Deadline on August 25, 2025 for HIMS Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm
Published: August 01, 2025 by: PRNewsWire
Sentiment: Neutral
RADNOR, Pa. , Aug. 1, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ("Hims & Hers") (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the "Class Period").
Read More
Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS is transforming digital healthcare with AI-driven care, a booming subscriber base, and new tech leadership.
Read More
Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , July 31, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 31, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors.
Read More
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 31, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 29, 2025 and June 23, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
Read More
Hims & Hers Health, Inc. (HIMS) Alleged “Deceptive” Marketing of Wegovy® Triggers Securities Class Actions – HIMS Investors with Losses Encouraged to Contact Hagens Berman
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, July 30, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. The cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025.
Read More
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers benefits from strong product demand and subscriber growth ahead of second-quarter 2025 earnings, fueled by weight loss and specialty care uptake.
Read More
DEADLINE ALERT for HIMS, IRBT, CNC, BHVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
BENSALEM, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
HIMS INVESTORS: Hims & Hers Health, Inc. (NYSE:HIMS) Investors may have been Affected by Fraud – Contact BFA Law by August 25 about Potentially Recovering Losses
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.
Read More
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS
Published: July 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and NEW ORLEANS, July 29, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased the Company's securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.
Read More
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
Published: July 29, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 29, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), of the important August 25, 2025 lead plaintiff deadline. So what: If you purchased Hims common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Deadline Alert: Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: July 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, July 29, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”).
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Medical - Equipment & Services
- CEO Andrew Dudum
- Employees 1637